Search results
Results from the WOW.Com Content Network
Ambroxol is indicated as "secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport. It promotes mucus clearance, facilitates expectoration and eases productive cough, allowing patients to breathe freely and deeply". [2] Ambroxol hydrochloride tablets in Japan
Clenbuterol is approved for use in some countries as a bronchodilator for asthma. [medical citation needed] Clenbuterol is a β 2 agonist with some structural and pharmacological similarities to epinephrine and salbutamol, but its effects are more potent and longer-lasting as a stimulant and thermogenic drug.
Common side effects of Asciminib are symptoms of a cold, muscle pain, joint pain, bone pain, fatigue, nausea, diarrhea, rash as well as the patient displaying abnormal blood tests. [14] Serious side effects of the medication include high blood pressure, low blood cell count, problems with the pancreas, and heart issues. [ 14 ]
For premium support please call: 800-290-4726 more ways to reach us
Levosalbutamol's bronchodilator properties give it indications in treatment of COPD (chronic obstructive pulmonary disease, also known as chronic obstructive lung disease) and asthma. Like other bronchodilators, it acts by relaxing smooth muscle in the bronchial tubes , and thus shortening or reversing an acute "attack" of shortness of breath ...
Oxeladin is a cough suppressant. [1] It is a highly potent and effective drug used to treat all types of cough of various etiologies. It is not related to opium or its derivatives, so treatment with oxeladin is free of risk of dependence or addiction.
Rolapitant (INN, [2] trade name Varubi / v ə ˈ r uː b i / və-ROO-bee in the US and Varuby in the European Union) is a drug originally developed by Schering-Plough and licensed for clinical development by Tesaro, which acts as a selective NK 1 receptor antagonist (antagonist for the NK 1 receptor). [3]
In animal and human studies, it has shown similar efficacy to theophylline but with significantly fewer side effects. [5] In February 2014, the US FDA granted an orphan drug designation to doxofylline for the treatment of bronchiectasis following the submission of an application by Alitair Pharmaceuticals, in May 2013.